TCM
RGNX icon

Tekla Capital Management’s Regenxbio RGNX Stock Holding History

Tekla Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-21,700
Closed -$843K – 192
2021
Q2 		$843K Hold
21,700
– – 0.03% 173
2021
Q1 		$740K Hold
21,700
– – 0.03% 183
2020
Q4 		$984K Hold
21,700
– – 0.03% 179
2020
Q3 		$597K Hold
21,700
– – 0.02% 193
2020
Q2 		$799K Hold
21,700
– – 0.03% 202
2020
Q1 		$703K Sell
21,700
-13,800
-39% -$575K 0.03% 186
2019
Q4 		$1.45M Sell
35,500
-73,748
-68% -$2.91M 0.06% 166
2019
Q3 		$3.89M Buy
109,248
+96,447
+753% +$3.91M 0.17% 99
2019
Q2 		$658K Buy
+12,801
New +$639K 0.03% 177

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Tekla Capital Management's RGNX Position: Q3 2021 in Review

Tekla Capital Management sold out of Regenxbio (RGNX) in Q3 2021, closing a stake of 21,700 shares — an estimated $843K sold.

Tekla Capital Management first reported a position in RGNX in Q2 2019 and held it in 9 quarters. The position peaked at $3.89M in Q3 2019. 182 funds tracked by Wall St. Rank hold RGNX as of Q3 2021.

  • Tekla Capital Management reported no remaining Regenxbio position as of Q3 2021 after selling out during the quarter.
  • Tekla Capital Management sold 21,700 Regenxbio shares in Q3 2021, an estimated $843K.
  • Tekla Capital Management first reported a position in Regenxbio in Q2 2019 and held it in 9 quarters.
  • Tekla Capital Management's Regenxbio position peaked at $3.89M in Q3 2019.
  • 182 funds tracked by Wall St. Rank held Regenxbio as of Q3 2021.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.